Skip to main content
. 2019 Feb 26;10:183. doi: 10.3389/fimmu.2019.00183

Figure 6.

Figure 6

MDSCs infusion ameliorates xenogeneic GVHD. (A) Experimetnal scheme. NSG mice were administered with/without sublethal irradiation (200 cGy) at day−1 and 1 × 106 human PBMCs were infused at day 0. The NSG mice were administered either 1 × 106, 2.5 × 106, 5 × 106 MDSCs (MDSCs mice) or PBMCs only (GVHD mice) at day 21 and 24. (B) Condition of fur: MDSCs mice vs. GVHD mice at day 35 and 70. (C) Overall survival. At a median of 100 days after PBMCs infusion, MDSCs mice were > 60% as compared with <0% for GVHD mice (GVHD vs. MDSCs 1 × 106 = 0.0070, GVHD vs. MDSCs 2.5 × 106 = 0.0156, GVHD vs. MDSCs 5 × 106 = 0.0059; log-rank test; n = 5 mice/group). Data represent one experiment of two independent experiments (MDSCs vs. GVHD **p < 0.01; log-rank test; n = 5 mice/group). (D) The degree of GVHD was recorded daily using a scoring system that summed changes in five clinical parameters: weight loss, posture, physical activity, fur texture, and skin integrity. The MDSCs mice showed lower GVHD score (MDSCs vs. GVHD ***p < 0.001). (E) The weight was measured every other day and the MDSCs treatment attenuates a weight loss (MDSCs vs. GVHD ***p < 0.001). Data are mean ± S.E.M. of two independent experiments.